NASDAQ:BGNE

Delisted

Beigene Stock News

Healthcare > Biotechnology

Buy BGNE

*Your capital is at risk

$184.71

+0 (+0%)

At Close: Mar 28, 2025

BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia

03:00am, Friday, 11'th Jun 2021

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines wo

Drug Startups Eye Quicker Profits Under China's New Fast-Track Approvals

02:01pm, Wednesday, 09'th Jun 2021

A recent regulatory overhaul designed to speed up development and approval of new drugs in China has been welcomed by global pharma giants and local startups alike, aimed at bringing their latest cutt

BeiGene, Shoreline Biosciences Ink Development Pact For NK Cell Therapies In Cancer

08:35am, Wednesday, 09'th Jun 2021

Shoreline Biosciences Inc and BeiGene Ltd (NASDAQ: BGNE) have announced an exclusive worldwide strategic collaboration to develop and commercialize a portfolio of NK-based cell therapeutics with

BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors

05:00pm, Monday, 07'th Jun 2021

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medic

BeiGene CEO on Covid Collaborations, Regulation, China

10:07pm, Wednesday, 02'nd Jun 2021

Jun.02 -- John Oyler, co-founder, chief executive officer and chairman at BeiGene Ltd., a global pharmaceutical and biotechnology company, discusses the company's partnerships on covid therapies, glob

BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021

10:00am, Tuesday, 01'st Jun 2021

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's ALPINE trial of BRUKINSA (zanubrutinib) versus ibrutinib in chronic lymphocytic leukemia will be featured in EHA2021 Presidential

Week In Review: LianBio Acquires 2 IBD Candidates In $218 Million Deal

11:15pm, Sunday, 23'rd May 2021

LianBio, a Princeton-Shanghai company, in-licensed Greater China rights for two inflammatory bowel disease candidates from Landos Biopharma. Ji Xing Pharma of Shanghai acquired Greater China rights to

BeiGene's Tislelizumab Shows Progression-Free Survival Benefit in Type Of Head & Neck Cancer

08:21am, Friday, 21'st May 2021

BeiGene Ltd (NASDAQ: BGNE) has announced topline results from the Phase 3 RATIONALE 309 trial evaluating tislelizumab combined with chemotherapy as a first-line treatment of recurrent or metastat

BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

07:00am, Friday, 21'st May 2021

BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting

05:00pm, Wednesday, 19'th May 2021

BeiGene's Brukinsa US Application For Expanded Use Under FDA Review

08:06am, Wednesday, 19'th May 2021

The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application for Brukinsa (zanubrutinib) for marginal zone lymphoma (MZL) and granted priority review. The applica

BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma

07:00am, Wednesday, 19'th May 2021

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by